Dianthus Therapeutics, Inc. (DNTH) News
Follow Dianthus Therapeutics, Inc. (DNTH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. NASDAQ:DNTH, a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment
NEWS | Sep 29, 2026, 12:09 PM UTC
L
DNTH: Strong clinical data and pipeline expansion position the company for major neuromuscular market growth
Claseprubart has delivered robust clinical results in MG and CIDP, prompting accelerated trial timelines and strategic trial design changes. The pipeline is expanding with DNTH212 and DNTH312, targeting broader neuromusc
EQUITY | Sep 10, 2026, 01:59 PM UTC
L
DNTH: Claseprubart's strong clinical results and pipeline advances are driving rapid growth and expansion
Claseprubart has delivered robust efficacy in MG and CIDP, accelerating trial timelines and market cap growth. The pipeline, including DNTH212 and DNTH312, is advancing rapidly, with MMN and broader neuromuscular indicat
EQUITY | Sep 10, 2026, 01:32 PM UTC
L
DNTH: Advancing neuromuscular pipeline with strong clinical data, key catalysts ahead, and robust cash runway
Significant pipeline progress was highlighted, with positive clinical data for claseprubart in MG and CIDP, and key MMN results expected soon. The company is well-positioned in competitive neuromuscular markets, advancin
EQUITY | Sep 09, 2026, 09:59 PM UTC
L
DNTH: Multiple clinical milestones and strong financials position the pipeline for major neuromuscular market impact
Significant pipeline progress was highlighted, including positive clinical data for claseprubart in MG and CIDP, with MMN phase II results and several key updates expected by year-end. The company is well-positioned in c
EQUITY | Sep 09, 2026, 09:28 PM UTC
L
Citigroup initiates Buy on Dianthus Therapeutics
Citigroup initiated a Buy rating on Dianthus Therapeutics, according to Benzinga ratings actions.
EQUITY | Sep 04, 2026, 01:22 PM UTC
L
Dianthus Therapeutics announces equity inducement grants under Nasdaq Rule 5635(c)(4)
Dianthus Therapeutics said it granted equity awards as inducements under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 09:07 PM UTC
L
DNTH announces inducement grants under Nasdaq Rule 5635(c)(4)
Dianthus Therapeutics (DNTH) announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 09:00 PM UTC
L
Dianthus Therapeutics to participate in three investor conferences in September
Dianthus Therapeutics said it will participate in three investor conferences during September, beginning Sept. 2026, as part of its planned investor outreach.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
DNTH to participate in three investor conferences in September
Dianthus Therapeutics (DNTH) will participate in three investor conferences during September.
EQUITY | Sep 01, 2026, 12:01 PM UTC
L
DNTH - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
DNTH - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
EARNINGS | Aug 04, 2026, 08:01 PM UTC
M
Dianthus Therapeutics Announces DNTH312
Dianthus launches new therapy for autoimmune diseases
EQUITY | Aug 04, 2026, 11:01 AM UTC